Health Care Distributors

ZHEJIANG ZHENYUAN

ZHEJIANG ZHENYUAN released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 440.52 M, actual EPS CNY -0.0653

ZHEJIANG ZHENYUAN released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 495.98 M, actual EPS CNY -0.1133

ZHEJIANG ZHENYUAN released FY2025 earnings on April 28 After-Market (BJT), actual revenue CNY 2.276 B, actual EPS CNY 0.07

ZHEJIANG ZHENYUAN FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

ZHEJIANG ZHENYUAN to Release FY2025 Earnings on April 29 After-Market BJT

ZHEJIANG ZHENYUAN released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 496.36 M, actual EPS CNY -0.0005

ZHEJIANG ZHENYUAN released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 1.78 B, actual EPS CNY 0.1689

Zhejiang Zhenyuan to Release FY2025 Q3 Earnings on October 31 After-Market BJT

ZHEJIANG ZHENYUAN released FY2025 Q2 earnings on August 22 During-Market (BJT), actual revenue CNY 531.6 M, actual EPS CNY 0.0621

ZHEJIANG ZHENYUAN released FY2025 Semi-Annual Earnings on August 22 During-Market (BJT), actual revenue CNY 1.283 B, actual EPS CNY 0.17

ZHEJIANG ZHENYUAN to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Zhejiang Shen Yuan Responds to Questions about Ester Compound Analgesic Effect and Synthetic Biology Technology Mastery

Zhejiang Zhenyuan Submits Stock Issuance Response to Shenzhen Stock Exchange

Zhejiang Zhenyuan's Synthetic Biology Project in Shangyu Expected to Start Production in Q3

Zhejiang Zhenyuan Responds to Uncertain Stock Issuance Recipients

Investors Question Zhejiang Shenyuan's Business Strategy

ZHEJIANG ZHENYUAN released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 751.67 M, actual EPS CNY 0.1074

ZHEJIANG ZHENYUAN released FY2024 earnings on April 28 After-Market (BJT), actual revenue CNY 3.741 B, actual EPS CNY 0.1

ZHEJIANG ZHENYUAN released FY2024 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 889.06 M, actual EPS CNY -0.0228

Zhejiang Zhenyuan FY2025 Q1 Earnings Release on April 29 After-Market BJT

000705

ZHEJIANG ZHENYUAN: On April 16, the company received a 'Notice of Custody' and a 'Notice of Case Filing' from the supervisory authority. Wei Min, a director and deputy general manager of the company, has been subjected to investigation and custody measures

Wallstreetcn

According to the Zhitong Finance APP, Zhejiang Zhenyuan announced that since the company disclosed the issuance of shares to specific targets, the company and relevant intermediary institutions have actively promoted various tasks. Now, considering the current capital market environment and the company's overall development plan, after fully communicating and prudently analyzing with relevant parties, the company has decided to terminate the issuance of shares to specific targets and has proactively applied to the Shenzhen Stock Exchange to withdraw the relevant application documents

Zhitong

ZHEJIANG ZHENYUAN terminates the issuance of stocks to specific objects and withdraws the application documents

On August 27th, ZHEJIANG ZHENYUAN stated on the interactive platform that the S1 production line of Zhenyuan Biotechnology is scheduled to officially start production by the end of August 2025

ZHEJIANG ZHENYUAN: The S1 production line is scheduled to officially start production at the end of August

ZHEJIANG ZHENYUAN stated on the interactive platform that the synthetic biology project of Zhenyuan Biotech is expected to be put into production in the third quarter

ZHEJIANG ZHENYUAN: The synthetic biology project of Zhenyuan Bio is expected to be put into production in the third quarter

002940

The synthetic biology concept is gaining strength. As of 10:16 AM, ZHEJIANG ZHENYUAN and ALK have reached the daily limit, Boji Pharmaceutical has risen over 10%, and Biological Shares, Kexing Pharmaceutical, and Hongbo Pharmaceutical have all increased by over 5%

The synthetic biology concept strengthens, ALK hits the limit up

002900

000513

01513

In the afternoon, the pharmaceutical stocks continued to rise, with both innovative drugs and generic drugs performing well. Stocks such as LIVZON GROUP, MEDISAN, Qianhong Pharmaceutical, Wanbangde, Asia-Pacific Pharmaceutical, and ZHEJIANG ZHENYUAN all hit the daily limit, while Guangshengtang, Laimei Pharmaceutical, and Wohu Biological rose over 10%. On the news front, the National Organization for Drug Procurement Office announced the selection of the 11th batch of centralized procurement varieties on the 15th. After three stages of screening, 55 varieties were included in the reporting scope of the 11th batch of centralized procurement. The procurement rules will generally adhere to the principles of "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition."

MEDISAN

LIVZON GROUP

LIVZON PHARMA

Pharmaceutical stocks continued to rise in the afternoon, with LIVZON GROUP and nearly ten other stocks hitting the daily limit

ZHEJIANG ZHENYUAN stated on the interactive platform that the innovative new drug for cancer pain treatment is still in the exploratory research stage and there are no plans for market launch at this time

301017

603108

600833

002727

The pharmaceutical commercial sector has declined in the short term, with NO.1 PHARMACY dropping over 6%, and YIXINTANG, ZHEJIANG ZHENYUAN, SYPM, Runda Medical, and others following suit

SYPM

Runda Medical

NO.1 PHARMACY

YIXINTANG

The pharmaceutical commercial sector has seen a short-term decline, with NO.1 PHARMACY dropping over 6%

000411

000950

000028

000078

The pharmaceutical commercial sector saw a short-term surge, with YIXINTANG hitting the limit up, and Sinopharm Accord, NEPTUNUS, INT'L GROUP, ZHEJIANG ZHENYUAN, CQP, and others all rising

INT'L GROUP

Sinopharm Accord

NEPTUNUS

The pharmaceutical commercial sector has seen a short-term surge, with YIXINTANG hitting the limit up

On March 28th, ZHEJIANG ZHENYUAN announced that the company's board of directors recently received a written report submitted by Vice Chairman and General Manager Chai Jun. Due to a job transfer, Chai Jun has applied to resign from his positions as Vice Chairman and General Manager of the company, and after his resignation, he will not hold any positions in the company or its subsidiaries. Chai Jun's resignation report will take effect from the date it is delivered to the board of directors. The relevant responsibilities of the General Manager will be temporarily performed by the company's Chairman Eddie Wu

ZHEJIANG ZHENYUAN: Chai Jun resigned as vice chairman and general manager due to job transfer

ZHEJIANG ZHENYUAN(000705.SZ)